Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss 400 Inquiries

Product Description
Retatrutide is a novel synthetic triple‑receptor agonist polypeptide raw material, appearing as white lyophilized crystalline powder with pharmaceutical purity ≥99% determined by HPLC. It is a groundbreaking triple‑hormone agonist capable of activating GLP‑1, GIP and GCGR receptors concurrently, delivering more potent metabolic benefits compared with dual‑target polypeptide molecules. Fatty‑acid side‑chain modification enables high‑affinity binding to plasma albumin, realizing prolonged circulating half‑life for convenient once‑weekly application. Rigorous impurity management secures consistent batch‑to‑batch performance, applicable for lyophilized formulations, pharmaceutical development and biomedical lab‑scale research. Supported by sufficient pharmacological validation and favorable solubility profile, it is extensively utilized by global research institutions for anti‑obesity and metabolic‑disorder formulation development.
Core Efficacy
Dual activation of GLP‑1 and GIP receptors works synergistically to slow gastric emptying, extend satiety time, curb cravings for high-sugar and high-fat food, naturally cut calorie intake and realize continuous healthy weight loss with remarkable fat-reducing effects on visceral fat and abdominal fat.
Regulates blood glucose in a glucose-dependent manner, promotes  secretion only when blood sugar rises, inhibits abnormal glucagon secretion, effectively stabilizes postprandial blood glucose spikes and HbA1c level, safely improves glycemic status of type 2 diabetic patients without hypoglycemia risk
Optimizes overall lipid metabolism, lowers triglycerides and bad cholesterol levels, alleviates hepatic fat deposition, improves non-alcoholic fatty liver conditions and reduces risks of metabolic syndrome and fatty liver disease.
Long-cycle efficacy design allows subcutaneous once per week, simplifies administration schedule and greatly improves patient medication compliance compared with daily  weight-loss peptides.
Improves  sensitivity and relieves resistance fundamentally, delaying the progression of prediabetes to confirmed type 2 diabetes for sub-health populations with impaired glucose tolerance.